Gilead Sciences | GILD - Процентные расходы





Процентные расходы Изменить Дата
AbbVie USD 688M 58M 2026-09
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
ALKERMES USD 27.55M 1.63M 2026-09
Alnylam Pharmaceuticals USD -84.37M 166.42M 2026-09
Amgen USD 653M 94.99B 2026-09
Biogen USD 72.6M 12.6M 2025-06
BioMarin Pharmaceutical USD 55.63M 7.67M 2026-09
Bristol-Myers Squibb USD 403M 4M 2026-09
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 316M 201.3M 2026-09
Gilead Sciences USD 269M 22M 2026-09
GlaxoSmithKline GBP 219M 98M 2026-09
Glaxosmithkline GBP 264.74M 72.01M 2026-09
Incyte USD 605K 23K 2026-09
J&J USD 43M 25M 2026-03
Merck USD 525M 46M 2026-06
Moderna USD 10.96B 527M 2026-06
Neurocrine Biosciences USD 300K 2.6M 2026-09
Novartis USD 468M 6M 2026-09
Pfizer USD 662M 5M 2026-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Puma Biotechnology USD 3.37M 11K 2024-06
Regeneron Pharmaceuticals USD 11M 1.9M 2026-06
Sangamo BioSciences 97.56M 11.39M 2025-06
Sanofi EUR 222M 65M 2026-09
Sarepta Therapeutics USD 21.51M 205K 2026-06
United Therapeutics USD 2.9M 200K 2026-06
Vertex Pharmaceuticals USD 36M 32.7M 2026-09